Add a GLP-1 Receptor Agonist to Your Farxiga
Your HbA1c of 7.8% (up from 7.7%) on Farxiga 10 mg alone indicates inadequate glycemic control, and you need to add a second medication—specifically, a GLP-1 receptor agonist is the preferred next step. 1
Why Add a GLP-1 Receptor Agonist?
The 2022 ADA/KDIGO consensus guidelines are explicit: when patients fail to achieve glycemic targets on metformin and/or an SGLT2 inhibitor (like Farxiga), adding a long-acting GLP-1 receptor agonist is the preferred strategy 1. This recommendation prioritizes:
- Cardiovascular protection: GLP-1 receptor agonists reduce major adverse cardiovascular events (MACE), with particularly strong benefits in patients with chronic kidney disease 1
- Weight loss: Unlike many diabetes medications, GLP-1 RAs promote significant weight reduction 2
- No hypoglycemia risk: When used without insulin or sulfonylureas, hypoglycemia is minimal 2
- Kidney protection: These agents reduce albuminuria and slow eGFR decline 1
Specific GLP-1 RA Options
Choose based on your preferences and cardiovascular status:
- Semaglutide (injectable weekly or oral daily): Proven cardiovascular benefit, no dose adjustment needed for kidney function 1
- Dulaglutide (injectable weekly): Proven cardiovascular benefit, convenient once-weekly dosing 1
- Liraglutide (injectable daily): Proven cardiovascular benefit, particularly strong MACE reduction in patients with reduced kidney function 1
All of these agents require no dose adjustment for kidney function and can be safely combined with Farxiga 1.
Why Not Just Increase or Change Your Current Regimen?
Farxiga Alone is Insufficient
Your HbA1c rising from 7.7% to 7.8% demonstrates that Farxiga monotherapy cannot achieve adequate glycemic control. The FDA label confirms that Farxiga typically reduces HbA1c by only 0.5-0.8% 3, and you've already reached its maximum effect. SGLT2 inhibitors like Farxiga have modest glucose-lowering efficacy (0.4-1.0% HbA1c reduction) 4, which is clearly insufficient for your needs.
Don't Wait—Act Now
The 2018 ADA/EASD consensus emphasizes that therapeutic inertia is a major problem in diabetes management 2. Your HbA1c is above target and trending upward—this is the exact scenario requiring treatment intensification. Waiting will only allow further glycemic deterioration and increase your risk of complications.
What About Other Options?
Why Not Metformin First?
While metformin is typically first-line therapy, you're already on Farxiga, which provides crucial cardiovascular and kidney protection 1. The guidelines support continuing your SGLT2 inhibitor and adding a GLP-1 RA rather than switching to metformin, especially if you have or are at risk for cardiovascular disease or chronic kidney disease.
Why Not Insulin?
Insulin would be appropriate if your HbA1c were >10% or you had symptoms of hyperglycemia 2, 5. At 7.8%, you're not in that category. GLP-1 RAs offer superior benefits: weight loss instead of weight gain, no hypoglycemia risk, and proven cardiovascular protection 2.
Why Not DPP-4 Inhibitors or Sulfonylureas?
These are inferior choices:
- DPP-4 inhibitors have weaker HbA1c reduction (similar to what you need) and lack cardiovascular benefits 2
- Sulfonylureas cause hypoglycemia and weight gain, with no cardiovascular or kidney protection 2
Important Considerations
Monitor for Side Effects
GLP-1 RAs commonly cause gastrointestinal side effects (nausea, vomiting, diarrhea), especially during dose titration 6. These typically improve over 4-8 weeks. Start at the lowest dose and titrate slowly.
Contraindications
Do not use GLP-1 RAs if you have:
- Personal or family history of medullary thyroid cancer 6
- Multiple endocrine neoplasia syndrome type 2 6
Continue Your Farxiga
Do not stop Farxiga 1. The combination of SGLT2 inhibitor plus GLP-1 RA provides:
- Complementary mechanisms of action
- Additive HbA1c reduction (expect 1.0-1.5% total reduction) 2
- Dual cardiovascular and kidney protection
- Synergistic weight loss effects
Expected Outcomes
With the addition of a GLP-1 RA to your Farxiga:
- HbA1c reduction: Expect an additional 0.8-1.5% decrease, bringing you well below 7.0% 1, 2
- Weight loss: 2-5 kg over 6 months 2
- Blood pressure: Further modest reduction 7
- Cardiovascular risk: Significant reduction in MACE 1